Profile data is unavailable for this security.
About the company
Henan Taloph Pharmaceutical Stock Co Ltd is a China-based company principally engaged in the research and development, manufacturing and sales of pharmaceuticals. The Company operates four segments. Pharmaceutical Manufacturing segment is mainly engaged in pharmaceutical preparations and Chinese herbal medicine slices business. Its products include Shuanghuanglian oral liquid series, Shuangjinlian mixture, Xiaoer Qingre Zhike oral liquid, Xiaoer Tuire oral liquid, Danshen oral liquid, Shengmaiyin, Fufang Yimu oral liquid, and various Chinese herbal medicine slices. Pharmaceutical and Medicinal Materials Circulation segment is mainly engaged in fresh processing business and traceable medicinal materials trading. Pharmaceutical Research and Development Services segment mainly provides technical services such as preclinical pharmaceutical research, clinical contract research organization (CRO) research, and registration application. Other segment is mainly engaged in investment business.
- Revenue in CNY (TTM)1.79bn
- Net income in CNY46.95m
- Incorporated1998
- Employees2.21k
- LocationHenan Taloph Pharmaceutical Stock Co LtdNo. 8Jinsuo RoadHi-Tech Industrial Development ZoneZHENGZHOU 450001ChinaCHN
- Phone+86 37 167992262
- Fax+86 37 167993600
- Websitehttp://www.taloph.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beijing Kawin Technol Sha-hld Co Ltd | 1.15bn | 136.81m | 3.74bn | 600.00 | 27.70 | 2.04 | -- | 3.26 | 0.789 | 0.789 | 6.61 | 10.73 | 0.4166 | 1.52 | 2.64 | 1,910,937.00 | 5.26 | 5.55 | 7.12 | 7.14 | 81.89 | 84.98 | 12.64 | 9.40 | 2.55 | -- | 0.2017 | 45.97 | -12.87 | 8.32 | 22.18 | 21.60 | 40.30 | -- |
| Zhejiang Cheng Yi Pharmaceutical Co Ltd | 790.86m | 226.35m | 3.79bn | 738.00 | 16.55 | 2.87 | -- | 4.79 | 0.6997 | 0.6997 | 2.46 | 4.04 | 0.4508 | 1.95 | 20.88 | -- | 13.02 | 11.48 | 15.87 | 14.03 | 68.99 | 69.02 | 28.88 | 24.63 | 0.985 | -- | 0.0808 | 37.22 | 6.36 | 0.9546 | 23.21 | 8.84 | -20.09 | 11.39 |
| Shanghai Shen Lian Biomedical Corp | 292.81m | -30.34m | 3.84bn | 391.00 | -- | 2.72 | -- | 13.11 | -0.0739 | -0.0739 | 0.713 | 3.43 | 0.1864 | 1.42 | 0.9144 | 748,865.90 | -2.21 | 3.53 | -2.40 | 3.80 | 57.36 | 73.49 | -11.87 | 16.93 | 3.64 | -- | 0.0106 | 43.52 | 0.6394 | 3.63 | -241.95 | -- | -3.99 | -- |
| Henan Taloph Pharmaceutical Stock Co Ltd | 1.79bn | 46.95m | 3.89bn | 2.21k | 76.71 | 2.44 | -- | 2.18 | 0.0884 | 0.0884 | 3.31 | 2.78 | 0.4791 | 2.74 | 1.60 | 807,429.60 | 1.45 | 0.3241 | 3.13 | 0.6105 | 23.45 | 26.22 | 3.02 | 0.6331 | 0.9038 | 1.86 | 0.3592 | 52.82 | -6.21 | 8.16 | 16.00 | 2.61 | -19.14 | -- |
| Shanghai MicuRx Pharmaceutical Co Ltd | 136.70m | -342.96m | 4.11bn | 188.00 | -- | 15.93 | -- | 30.05 | -0.5197 | -0.5197 | 0.2077 | 0.3929 | 0.161 | 0.4661 | 3.95 | 727,105.00 | -40.40 | -31.40 | -53.04 | -35.41 | 84.26 | 82.42 | -250.89 | -503.67 | 2.15 | -406.30 | 0.5862 | -- | 43.51 | -- | -4.65 | -- | 51.72 | -- |
| Holder | Shares | % Held |
|---|---|---|
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 3.24m | 0.57% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 2.13m | 0.38% |
| Broad Fund Management Co. Ltd.as of 30 Jun 2025 | 1.25m | 0.22% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 847.20k | 0.15% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 622.73k | 0.11% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2025 | 346.07k | 0.06% |
| Hwabao WP Fund Management Co., Ltd.as of 30 Jun 2025 | 221.60k | 0.04% |
| First Seafront Fund Management Co., Ltd.as of 30 Jun 2025 | 86.90k | 0.02% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2025 | 58.80k | 0.01% |
| Western Leadbank Fund Management Co., Ltdas of 30 Jun 2025 | 52.00k | 0.01% |
